Postmarketing Surveillance Study With MOBEC®
Completed
- Conditions
- Osteoarthritis
- Interventions
- Drug: MOBEC
- Registration Number
- NCT02182726
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The aim of the study is to investigate
* the indication for MOBEC in a dose of 15 mg per day
* the treatments patients were receiving before switching to 15 mg MOBEC
* how treatment with 15 mg is assessed compared with previous treatment
* how effective and safe treatment with 15 mg MOBEC is considered
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4760
Inclusion Criteria
-
An indication for a treatment with 15 mg MOBEC of at least four weeks
- the symptomatic short-term treatment of osteoarthritis
- the symptomatic long-term treatment of rheumatoid arthritis (chronic polyarthritis); restriction: the recommended dose for long-term treatment of elderly patients is 7.5 mg)
- the symptomatic treatment of ankylosing spondylitis
Exclusion Criteria
- Treatment with MOBEC prior to the start of the study
- Patients with any of the general or specific contraindications of MOBEC
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description MOBEC MOBEC -
- Primary Outcome Measures
Name Time Method Assessment of efficacy by physician on a 5-point scale up to week 8 Nature and incidence of adverse drug reactions (ADR) up to week 8 Assessment of tolerability by physician on a 5-point scale up to week 8
- Secondary Outcome Measures
Name Time Method